Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease | MicrobiomeTrials← Back to trialsNCT07281456
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-18Est. Completion: 2030-12-15
Enrollment target: 60 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Sjogren's SyndromeSalivary GlandPathogenesis
Background:
-Sjogren s Disease (formerly: Sjogrens Syndrome, Sj(SqrRoot)(Delta)gren s syndrome) is a disease that affec…
Bethesda, United States
Healthy VolunteerSjogren's SyndromeSalivary Gland Disease
Background:
\- Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a pe…
Bethesda, United StatesEst. completion Apr 1, 2032